Finishing line in sight for ICH reforms
This article was originally published in SRA
Up to four more medicines regulators and two additional pharmaceutical industry bodies have expressed an interest in joining the reformed International Conference on Harmonisation when it begins operating later this year*.
You may also be interested in...
Brazil and South Korea have been accepted as new regulatory members of the International Council for Harmonisation. This has raised expectations that ICH guidelines will gain full acceptance in both countries, making it easier for the global innovative pharmaceutical industry to market their products there.
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.
The UK Thalassaemia Society says that HTA body NICE fails to properly incorporate patient experiences into its decision making and that its patient engagement processes need reform. The marketing of Zynteglo, the gene therapy from bluebird bio for which the group is advocating, has just been temporarily suspended.